Drugs / PHH-1V81
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06181292 | Nov 2023 → Jun 2024 | COVID-19 | Hipra Scientific, S.L.U | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHH-1V81 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06181292 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate” NCT06181292 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06181292 ↗ |